Bristol-Myers Squibb has expanded multi-year agreement with Saladax Biomedical to develop and commercialize diagnostic assays for the early detection of Alzheimer's disease to include Ortho-Clinical Diagnostics.
The three companies will collaborate for the development and regulatory approvals for certain diagnostic assays, as per the agreement.
A seperate agreement is signed between Saladax and Ortho-Clinical Diagnostics for the commercialization of the assays.
Bristol-Myers Squibb Alzheimer disease lead and Neuroscience and Global Development vice president Jane Tiller said by pursuing the development of validated assays that could assist physicians in the diagnosis of Alzheimer’s disease, they can continue to advance the understanding and treatment of this devastating disease.
In May 2010, Bristol-Myers Squibb and Saladax have entered into an agreement to develop clinical diagnostic tests to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline.
Saladax has gained rights to commercialize the assays it develops.